296 related articles for article (PubMed ID: 25645689)
1. Rotenone decreases intracellular aldehyde dehydrogenase activity: implications for the pathogenesis of Parkinson's disease.
Goldstein DS; Sullivan P; Cooney A; Jinsmaa Y; Kopin IJ; Sharabi Y
J Neurochem; 2015 Apr; 133(1):14-25. PubMed ID: 25645689
[TBL] [Abstract][Full Text] [Related]
2. Determinants of buildup of the toxic dopamine metabolite DOPAL in Parkinson's disease.
Goldstein DS; Sullivan P; Holmes C; Miller GW; Alter S; Strong R; Mash DC; Kopin IJ; Sharabi Y
J Neurochem; 2013 Sep; 126(5):591-603. PubMed ID: 23786406
[TBL] [Abstract][Full Text] [Related]
3. The rat rotenone model reproduces the abnormal pattern of central catecholamine metabolism found in Parkinson's disease.
Landau R; Halperin R; Sullivan P; Zibly Z; Leibowitz A; Goldstein DS; Sharabi Y
Dis Model Mech; 2022 Jan; 15(1):. PubMed ID: 34842277
[TBL] [Abstract][Full Text] [Related]
4. 3,4-Dihydroxyphenylacetaldehyde potentiates the toxic effects of metabolic stress in PC12 cells.
Lamensdorf I; Eisenhofer G; Harvey-White J; Nechustan A; Kirk K; Kopin IJ
Brain Res; 2000 Jun; 868(2):191-201. PubMed ID: 10854571
[TBL] [Abstract][Full Text] [Related]
5. Dihydroxyphenylacetaldehyde Lowering Treatment Improves Locomotor and Neurochemical Abnormalities in the Rat Rotenone Model: Relevance to the Catecholaldehyde Hypothesis for the Pathogenesis of Parkinson's Disease.
Khashab R; Gutman-Sharabi N; Shabtai Z; Landau R; Halperin R; Fay-Karmon T; Leibowitz A; Sharabi Y
Int J Mol Sci; 2023 Aug; 24(15):. PubMed ID: 37569897
[TBL] [Abstract][Full Text] [Related]
6. Vesicular uptake blockade generates the toxic dopamine metabolite 3,4-dihydroxyphenylacetaldehyde in PC12 cells: relevance to the pathogenesis of Parkinson's disease.
Goldstein DS; Sullivan P; Cooney A; Jinsmaa Y; Sullivan R; Gross DJ; Holmes C; Kopin IJ; Sharabi Y
J Neurochem; 2012 Dec; 123(6):932-43. PubMed ID: 22906103
[TBL] [Abstract][Full Text] [Related]
7. The Catecholaldehyde Hypothesis for the Pathogenesis of Catecholaminergic Neurodegeneration: What We Know and What We Do Not Know.
Goldstein DS
Int J Mol Sci; 2021 Jun; 22(11):. PubMed ID: 34206133
[TBL] [Abstract][Full Text] [Related]
8. Benomyl, aldehyde dehydrogenase, DOPAL, and the catecholaldehyde hypothesis for the pathogenesis of Parkinson's disease.
Casida JE; Ford B; Jinsmaa Y; Sullivan P; Cooney A; Goldstein DS
Chem Res Toxicol; 2014 Aug; 27(8):1359-61. PubMed ID: 25045800
[TBL] [Abstract][Full Text] [Related]
9. Metabolic stress in PC12 cells induces the formation of the endogenous dopaminergic neurotoxin, 3,4-dihydroxyphenylacetaldehyde.
Lamensdorf I; Eisenhofer G; Harvey-White J; Hayakawa Y; Kirk K; Kopin IJ
J Neurosci Res; 2000 May; 60(4):552-8. PubMed ID: 10797558
[TBL] [Abstract][Full Text] [Related]
10. Decreased vesicular storage and aldehyde dehydrogenase activity in multiple system atrophy.
Goldstein DS; Sullivan P; Holmes C; Kopin IJ; Sharabi Y; Mash DC
Parkinsonism Relat Disord; 2015 Jun; 21(6):567-72. PubMed ID: 25829070
[TBL] [Abstract][Full Text] [Related]
11. The catecholaldehyde hypothesis: where MAO fits in.
Goldstein DS
J Neural Transm (Vienna); 2020 Feb; 127(2):169-177. PubMed ID: 31807952
[TBL] [Abstract][Full Text] [Related]
12. Comparison of Monoamine Oxidase Inhibitors in Decreasing Production of the Autotoxic Dopamine Metabolite 3,4-Dihydroxyphenylacetaldehyde in PC12 Cells.
Goldstein DS; Jinsmaa Y; Sullivan P; Holmes C; Kopin IJ; Sharabi Y
J Pharmacol Exp Ther; 2016 Feb; 356(2):483-92. PubMed ID: 26574516
[TBL] [Abstract][Full Text] [Related]
13. Products of oxidative stress inhibit aldehyde oxidation and reduction pathways in dopamine catabolism yielding elevated levels of a reactive intermediate.
Jinsmaa Y; Florang VR; Rees JN; Anderson DG; Strack S; Doorn JA
Chem Res Toxicol; 2009 May; 22(5):835-41. PubMed ID: 19388687
[TBL] [Abstract][Full Text] [Related]
14. Methylmercury impairs canonical dopamine metabolism in rat undifferentiated pheochromocytoma (PC12) cells by indirect inhibition of aldehyde dehydrogenase.
Tiernan CT; Edwin EA; Hawong HY; Ríos-Cabanillas M; Goudreau JL; Atchison WD; Lookingland KJ
Toxicol Sci; 2015 Apr; 144(2):347-56. PubMed ID: 25601988
[TBL] [Abstract][Full Text] [Related]
15. Biomarkers, mechanisms, and potential prevention of catecholamine neuron loss in Parkinson disease.
Goldstein DS
Adv Pharmacol; 2013; 68():235-72. PubMed ID: 24054148
[TBL] [Abstract][Full Text] [Related]
16. Aldehyde dehydrogenase inhibition generates a reactive dopamine metabolite autotoxic to dopamine neurons.
Doorn JA; Florang VR; Schamp JH; Vanle BC
Parkinsonism Relat Disord; 2014 Jan; 20 Suppl 1(0 1):S73-5. PubMed ID: 24262193
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of the oxidative metabolism of 3,4-dihydroxyphenylacetaldehyde, a reactive intermediate of dopamine metabolism, by 4-hydroxy-2-nonenal.
Florang VR; Rees JN; Brogden NK; Anderson DG; Hurley TD; Doorn JA
Neurotoxicology; 2007 Jan; 28(1):76-82. PubMed ID: 16956664
[TBL] [Abstract][Full Text] [Related]
18. Selective dopaminergic vulnerability: 3,4-dihydroxyphenylacetaldehyde targets mitochondria.
Kristal BS; Conway AD; Brown AM; Jain JC; Ulluci PA; Li SW; Burke WJ
Free Radic Biol Med; 2001 Apr; 30(8):924-31. PubMed ID: 11295535
[TBL] [Abstract][Full Text] [Related]
19. Semi-chronic increase in striatal level of 3,4-dihydroxyphenylacetaldehyde does not result in alteration of nigrostriatal dopaminergic neurones.
Legros H; Janin F; Dourmap N; Bonnet JJ; Costentin J
J Neurosci Res; 2004 Feb; 75(3):429-35. PubMed ID: 14743456
[TBL] [Abstract][Full Text] [Related]
20. Neuroprotective effects of aldehyde dehydrogenase 2 activation in rotenone-induced cellular and animal models of parkinsonism.
Chiu CC; Yeh TH; Lai SC; Wu-Chou YH; Chen CH; Mochly-Rosen D; Huang YC; Chen YJ; Chen CL; Chang YM; Wang HL; Lu CS
Exp Neurol; 2015 Jan; 263():244-53. PubMed ID: 25263579
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]